Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection

Gene Therapy

Volumn 14, Issue 17, 2007, Pages 1287-1297

  Anderson, J ^a   Akkina, R ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ARTICLE; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE CASSETTE; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL GENE THERAPY; TRANSGENE; VIRUS RESISTANCE; VIRUS STRAIN;

BIOLOGICAL MARKERS; CELLS, CULTURED; FLOW CYTOMETRY; GENE DELETION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; PHOSPHATIDYLSERINES; RECEPTORS, CCR5; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548133627     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302958     Document Type: Article

References (52)

1. Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000; 97: 10948-10953.
2. Lafeuillade A, Poggi C, Hittinger G, Chadapaud S. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med 2001; 2: 231-235.
3. Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi J. siRNAs, ribozymes, and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 2003; 23: 1997-2006.
4. Cagnon L, Rossi J. Down regulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Anti Nucl Acid Drug Dev 2000; 10: 251-261.
5. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Characterization of anti- CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 2000; 1: 244-254.
6. Bai J, Rossi J, Akkina R. Multivalent anti-CCR5 ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 2001; 17: 385-399.
7. Bai J, Banda N, Lee NS, Rossi J, Akkina R. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol Ther 2002; 6 770-782.
8. Ding SF, Lombardi R, Nazari R, Joshi S. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and transdominant negative mutant Gag and Env proteins. Front Biosci 2002; 7: A15-a28.
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
11. Sharp P. RNA interference-2001. Genes Dev 2001; 15: 485-490.
12. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500-505.
13. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
14. Jacque J, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
15. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type-1 replication by RNA interference. J Virol 2002; 76: 9225-9231.
16. Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002; 169 5196-5201.
17. Banerjea A, Li MJ, Bauer G, Remling L, Lee NS, Rossi J et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
18. Li M, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
19. Haasnoot PCJ, Cupac D, Berkhout B. Inhibition of virus replication by RNA interference. J Biomed Sci 2003; 10: 607-616.
20. Lee MM, Coburn G, McClure MO, Cullen BR. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003; 77: 11964-11972.
21. Anderson J, Banerjea A, Planelles V, Akkina R. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 2003; 19: 699-706.
22. Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 2003; 13: 303-312.
23. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16: 2385-2390.
24. Qin X, An DS, Chen ISY, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
25. Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003; 77: 7174-7181.
26. Butticaz C, Ciuffi A, Munoz M, Thomas J, Bridge A, Pebernard S et al. Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antiviral Ther 2003; 8: 373-377.
27. Cordelier P, Morse B, Strayer DS. Targeting CCR5 with siRNAs: Using recombinant SV40-derived vectors to protect macrophages and Microglia from R5-Tropic HIV. Oligonucleotides 2003; 13: 281-294.
28. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 2004; 11: 1703-1712.
29. Anderson J, Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005; 2: 1-12.
30. Anderson J, Akkina R. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology 2005; 9: 2: 53.
31. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
32. Liang WS, Maddukuri A, Teslovich TM, de la Fuente C, Agbottah E, Dadgar S et al. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2005; 9: 20.
33. Boden D, Pusch O, Lee F, Tucker L. Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531-11535.
34. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R. et al. Human Immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-2605.
35. Bieniasz PD, Cullen BR. Chemokine receptors and Human Immunodeficiency Virus infection. Front Biosci 1998; 3: 44-58.
36. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
37. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996; 86 267-377.
38. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
39. Naif HM, Cunningham AL, Alali M, Li S, Nasr N, Buhler MM et al. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Δ32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol 2002; 76: 3114-3124.
40. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 3: 326-330.
41. Boese Q, Leake D, Reynolds A, Read S, Scaringe S, Marshall WS et al. Mechanistic insights aid computational short interfering RNA design. Methods Enzymol 2005; 392: 73-96.
42. Vermeulen A, Behlen L, Reynolds A, Wolfson A, Marshall WS. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA 2005; 5: 674-682.
43. Naldini L. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
44. An DS, Koyanagi Y, Zhao JQ, Akkina R, Bristol G, Yamamoto N et al. High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. J Virol 1997; 71: 1397-1404.
45. Ailles LE, Naldini L. HIV-1 Derived Lentiviral Vectors. In: Trono D (ed). Lentiviral Vectors. Springer: Berlin, 2002, pp 31-48.
46. Yam P, Li S, Wu J, Hu J, Zaia J, Yee J. Design of HIV-1 vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002; 6: 770-782.
47. Mautino MR, Morgan RA. Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDs 2002; 16: 11-26.
48. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotech 2004; 23: 227-231.
49. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004; 101: 1892-1897.
50. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 7: 1188-1196.
51. An DS, Qin X-F, Auyeung VC, Mao SH, Kung SKP, Baltimore D et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006; 14: 494-504.
52. Castanotto D, Li H, Rossi J. Functional siRNA expression from transfected PCR products. RNA 2002; 8: 1454-1460.